 | | Vol. 12.00 – 4 January, 2023 |
| |
|
|
| Scientists found that CD96 was frequently expressed in tumor cells from clinical breast cancer samples. The CD96+ cancer cell subpopulations exhibited features of both breast CSCs and chemoresistance.
[Advanced Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers reported a nanotherapeutic strategy based on MnOx-loaded polydopamine nanobombs with chemodynamic, photodynamic, photothermal, and biodegradation properties to inhibit CSCs and non-CSCs concurrently.
[Small] |
|
|
|
| Scientists designed a study to reveal the effect and underlying mechanism of Josephin-2, a relatively newly defined deubiquitinating enzyme, in hepatocellular carcinoma progression.
[Genes & Genomics] |
|
|
|
| Investigators characterized BCSCs through the genetic profiling of different BCSCs phenotypic subsets to determine their related genetic pathways.
[Cancer Cell International] |
|
|
|
| The authors investigated the regulatory effect of the SUMO-specific protease 1 (SENP1)/methyltransferase-like 3 (METTL3)/MYC axis on the self-renewal of glioblastoma stem cells mediated by transcription factor Yin Yang 1 (YY1).
[Cancer Gene Therapy] |
|
|
|
| Scientists leveraged single-cell transcriptome sequencing data of six independent glioblastoma cohorts from public databases, and combined lineage and stemness features to identify primary glioblastoma stem cells.
[Stem Cells] |
|
|
|
| Researchers attempted to identify previously unrecognized CSC survival factors that could be used as druggable targets for breast CSCs apoptosis regulators isolated from the triple-negative breast cancer line.
[Cell Biology International] |
|
|
|
| High expression of ATP Binding Cassette subfamily C member 3 (ABCC3) was restricted to glioblastoma, with negligible levels in healthy brain tissue, and further correlated with tumor grade and stemness markers.
[Scientific Reports] |
|
|
|
| The authors demonstrated that cleavage and polyadenylation specificity factor 4 (CPSF4) promoted tumor-initiating phenotype and conferred chemoresistance to paclitaxel both in vitro and in vivo.
[Medical Oncology] |
|
|
|
|
| Investigators provide an overview of the available methods for assessing the efficacy of whole CSC-based vaccines on tumor development, metastasis, and survival rate.
[Stem Cells] |
|
|
|
|
| STEMCELL Technologies announced that its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honorable Mary Simon, the Governor General of Canada.
[STEMCELL Technologies] |
|
|
|
|
| March 6 – 8, 2023
Paris, France |
|
|
|
|
|
| | University Medical Center Freiburg – Freiburg, Germany |
|
|
|
| | Karolinska Institutet – Solna, Sweden |
|
|
|
| | Columbia University – New York, New York, United States |
|
|
|
| | US FDA – Silver Spring, Maryland, United States |
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
